加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$36.35
+US$0.04 · +0.11%
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
收盘时
US$36.35
+US$0.04 · +0.11%
盘后
US$36.35
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
日内区间
当前US$36.35
52周区间
当前US$36.35
盘中时间采用ET。市场数据可能有所延迟。
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
日内区间
当前US$36.35
52周区间
当前US$36.35
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 7.26亿 USD | 7.01亿 USD | 6.75亿 USD | 6.67亿 USD | 5.42亿 USD |
| 销货成本 | 1.5亿 USD | 1.7亿 USD | 1.85亿 USD | 1.99亿 USD | 1.4亿 USD |
| 毛利 | 5.77亿 USD | 5.31亿 USD | 4.9亿 USD | 4.68亿 USD | 4.01亿 USD |
| 研究与开发 | 1.17亿 USD | 8157.7万 USD | 7625.7万 USD | 8479.7万 USD | 5554.5万 USD |
| 销售、一般及管理费用 | 3.69亿 USD | 2.94亿 USD | 2.69亿 USD | 2.55亿 USD | 1.99亿 USD |
| 营业费用 | 5.43亿 USD | 6.04亿 USD | 4.03亿 USD | 4.08亿 USD | 3.11亿 USD |
| 利息收入 | 2273.2万 USD | 1968.9万 USD | 1144.4万 USD | 454.2万 USD | 89.6万 USD |
| 利息支出 | 1460.6万 USD | 1656.9万 USD | 1731万 USD | 3557.6万 USD | 2899.6万 USD |
| 折旧和摊销 | 9102.3万 USD | 7878.5万 USD | 7557.4万 USD | 9150.1万 USD | 2854.8万 USD |
| 营业利润 | 3330.3万 USD | −7337.1万 USD | 8767.5万 USD | 6002.4万 USD | 8992.4万 USD |
| 净利润 | 703.4万 USD | −9956万 USD | 4195.5万 USD | 1590.9万 USD | 4198万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$31.67
下跌空间 12.87%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM3749.06万0.05%787.4亿 USD0.19%US$277.9-0.37%
Avantis U.S. Small Cap Value ETFAVUV3434.69万0.11%308.51亿 USD0.25%US$119.94+0.25%
Vanguard Morningstar Total Stock Market ETFVTI3104.87万0.00%2.3万亿 USD0.03%US$381.57-0.10%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV2914.9万0.11%268.09亿 USD0.33%US$37.98+0.08%
Vanguard Morningstar Small-Cap ETFVB2222.8万0.01%1853亿 USD0.03%US$288.16-0.46%
Dimensional - US Targeted Value ETFDFAT1495.4万0.05%301.22亿 USD0.33%US$67.42+0.22%
Vanguard Morningstar Small-Cap Value ETFVBR1414.23万0.02%682亿 USD0.05%US$234.71+0.12%
Fidelity Enhanced Small Cap ETFFESM1408.58万0.21%64.1亿 USD0.28%US$45.24-0.48%iShares Russell 2000 ETFIWMAvantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIU.S. Small Cap Value Portfolio ETF Class SharesDFSVVanguard Morningstar Small-Cap ETFVBDimensional - US Targeted Value ETFDFATVanguard Morningstar Small-Cap Value ETFVBRFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
